174 related articles for article (PubMed ID: 34710285)
1. Novel treatment of endobronchial inflammatory myofibroblastic tumor in a child.
Reyes-Angel J; Rapkin LB; Simons JP; Muzumdar H
Pediatr Pulmonol; 2022 Jan; 57(1):330-332. PubMed ID: 34710285
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation.
Ogata M; Hatachi Y; Ogata T; Satake H; Imai Y; Yasui H
Intern Med; 2019 Apr; 58(7):1029-1032. PubMed ID: 30449794
[TBL] [Abstract][Full Text] [Related]
3. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.
Liu W; Duan Q; Gong L; Yang Y; Huang Z; Guo H; Niu X
Invest New Drugs; 2021 Feb; 39(1):278-282. PubMed ID: 32915420
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
Butrynski JE; D'Adamo DR; Hornick JL; Dal Cin P; Antonescu CR; Jhanwar SC; Ladanyi M; Capelletti M; Rodig SJ; Ramaiya N; Kwak EL; Clark JW; Wilner KD; Christensen JG; Jänne PA; Maki RG; Demetri GD; Shapiro GI
N Engl J Med; 2010 Oct; 363(18):1727-33. PubMed ID: 20979472
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic lymphoma kinase inhibitor therapy in the treatment of inflammatory myofibroblastic tumors in pediatric patients: Case reports and literature review.
Craig E; Wiltsie LM; Beaupin LK; Baig A; Kozielski R; Rothstein DH; Li V; Twist CJ; Barth M
J Pediatr Surg; 2021 Dec; 56(12):2364-2371. PubMed ID: 33676744
[TBL] [Abstract][Full Text] [Related]
6. Crizotinib in ALK
Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors.
Tothova Z; Wagner AJ
Curr Opin Oncol; 2012 Jul; 24(4):409-13. PubMed ID: 22664824
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report.
Nagumo Y; Maejima A; Toyoshima Y; Komiyama M; Yonemori K; Yoshida A; Fujimoto H
Int J Surg Case Rep; 2018; 48():1-4. PubMed ID: 29758320
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.
Qiu X; Montgomery E; Sun B
Hum Pathol; 2008 Jun; 39(6):846-56. PubMed ID: 18400254
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib combined with bronchoscopic interventional treatment in ALK-positive inflammatory myofibroblastic tumor of left main stem bronchus: a case report.
Zhang P; Wang C; Lv Z; Du M; Xu R
J Cardiothorac Surg; 2023 Nov; 18(1):318. PubMed ID: 37950305
[TBL] [Abstract][Full Text] [Related]
11. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.
Brivio E; Zwaan CM
Pediatr Blood Cancer; 2019 May; 66(5):e27645. PubMed ID: 30697903
[TBL] [Abstract][Full Text] [Related]
12. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.
Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M
Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
Schöffski P; Kubickova M; Wozniak A; Blay JY; Strauss SJ; Stacchiotti S; Switaj T; Bücklein V; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Lee CJ; Speetjens FM; Nzokirantevye A; Neven A; Kasper B
Eur J Cancer; 2021 Oct; 156():12-23. PubMed ID: 34392187
[TBL] [Abstract][Full Text] [Related]
14. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
Mossé YP; Voss SD; Lim MS; Rolland D; Minard CG; Fox E; Adamson P; Wilner K; Blaney SM; Weigel BJ
J Clin Oncol; 2017 Oct; 35(28):3215-3221. PubMed ID: 28787259
[TBL] [Abstract][Full Text] [Related]
15. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.
Alan O; Kuzhan O; Koca S; Telli TA; Basoglu T; Ercelep O; Filinte D; Sengul Y; Arikan H; Kaya S; Babacan NA; Dane F; Yumuk PF
J Oncol Pharm Pract; 2020 Jun; 26(4):1011-1018. PubMed ID: 31615346
[TBL] [Abstract][Full Text] [Related]
16. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
17. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma.
Montgomery EA; Shuster DD; Burkart AL; Esteban JM; Sgrignoli A; Elwood L; Vaughn DJ; Griffin CA; Epstein JI
Am J Surg Pathol; 2006 Dec; 30(12):1502-12. PubMed ID: 17122505
[TBL] [Abstract][Full Text] [Related]
19. Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report.
Comandini D; Catalano F; Grassi M; Pesola G; Bertulli R; Guadagno A; Spina B; Mascherini M; De Cian F; Pistoia F; Rebuzzi SE
Front Oncol; 2021; 11():658327. PubMed ID: 34211840
[TBL] [Abstract][Full Text] [Related]
20. Sustained complete response on crizotinib in primary lung inflammatory myofibroblastic tumor - Case report and literature review.
Mittal A; Gupta A; Dhamija E; Barwad A; Rastogi S
Monaldi Arch Chest Dis; 2021 Mar; 91(3):. PubMed ID: 33794589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]